Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

A CRISPR-based inducible system for VEGF repression for AMD

Shusheng Wang; Yao Tong; Yinga Wu; Jing Ma; Zunyi Zhang

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1951 – F0369. doi:

ARVO Annual Meeting Abstract June 2022

Crosstalk among Ferroptosis, Necroptosis, and Pyroptosis during oxidative stress-induced RPE Cell Death

Yao Tong; Yinga Wu; Jing Ma; Shusheng Wang

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3048 – F0419. doi:

ARVO Annual Meeting Abstract June 2022

MiRNA-24 represses TGF-β2 induced epithelial-mesenchymal transition (EMT), endothelial-mesenchymal transition (EndMT), and fibrosis program

Yinga Wu; Yao Tong; Katherine Byrnes; Qi Zhou; Jing Ma; Shusheng Wang

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3873. doi:

ARVO Annual Meeting Abstract June 2021

MiRNA-24 represses TGF-β2 induced epithelial-mesenchymal transition (EMT) and fibrosis in RPE cells

Yinga Wu; Katherine Brynn; Jing Ma; Shusheng Wang

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):309. doi:

ARVO Annual Meeting Abstract June 2021

Inhibition of RPE ferroptosis by necroptosis inhibitor Necrostatin-1

Yao Tong; Yinga Wu; Jing Ma; Shusheng Wang

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2713. doi:

Advertisement